Prognostic Usefulness of Myocardial Work in Patients with Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan

Heart failure (HF) is a major public health problem due to its high prevalence, major morbidity and mortality1. Sacubitril/Valsartan, an inhibitor of the angiotensin receptor-neprilysin2, has demonstrated a 20% relative reduction in cardiovascular death and a 16% relative risk reduction in all-cause mortality, when compared with Enalapril. This prognostic effect is associated with a striking improvement in left ventricular (LV) function and reverse remodelling3, which could be attributed to the afterload reduction induced by this treatment4.

Source: The American Journal of Cardiology - April 1, 2020 Category: Cardiology Authors: Yanis Bouali, Erwan Donal, Alban Gallard, Cl ément Laurin, Arnaud Hubert, Auriane Bidaut, Christophe Leclercq, Elena Galli Source Type: research